This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jin, H. Articles by Ashkenazi, A. Search for Related Content PubMed PubMed Citation Articles by Jin, H. Articles by Ashkenazi, A.

Apo2 Ligand/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Cooperates with Chemotherapy to Inhibit Orthotopic Lung Tumor Growth and Improve Survival

Departments of ¹ Molecular Oncology, ² Physiology, and ³ Pathology, Genentech, Inc., South San Francisco, California

Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) is a tumor necrosis factor superfamily member that induces apoptosis through the death receptors DR4 and/or DR5 in various cancer cell types but not in most normal cells. Several lung cancer cell lines express DR4 and DR5 and undergo apoptosis in vitro in response to Apo2L/TRAIL. We investigated the efficacy of recombinant soluble human Apo2L/TRAIL and its interaction with chemotherapy in xenograft models based on human NCI-H460 non-small cell lung carcinoma cells. In vitro, Taxol enhanced caspase activation and apoptosis induction by Apo2L/TRAIL. In vivo, Apo2L/TRAIL or Taxol plus carboplatin chemotherapy partially delayed progression of established subcutaneous tumor xenografts, whereas combined treatment caused tumor regression and a substantially longer growth delay. Apo2L/TRAIL, chemotherapy, or the combination of both inhibited growth of preformed orthotopic lung parenchymal tumors versus control by 60%, 57%, or 97%, respectively (all P < 0.01; n = 8–10). Furthermore, combination treatment improved day-90 survival relative to control (7 of 15 versus 1 of 15; P = 0.0003 by Mantel-Cox) as well as to Apo2L/TRAIL (3 of 14; P = 0.031) or chemotherapy (3 of 15; P = 0.035). These studies provide evidence for in vivo activity of Apo2L/TRAIL against lung tumor xenografts and underscore the potential of this ligand for advancing current lung cancer treatment strategies.

This article has been cited by other articles:

				I. Zinonos, A. Labrinidis, M. Lee, V. Liapis, S. Hay, V. Ponomarev, P. Diamond, A. C.W. Zannettino, D. M. Findlay, and A. Evdokiou Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer Mol. Cancer Ther., October 1, 2009; 8(10): 2969 - 2980. [Abstract] [Full Text] [PDF]

				M. R. Loebinger, A. Eddaoudi, D. Davies, and S. M. Janes Mesenchymal Stem Cell Delivery of TRAIL Can Eliminate Metastatic Cancer Cancer Res., May 15, 2009; 69(10): 4134 - 4142. [Abstract] [Full Text] [PDF]

				A. Labrinidis, P. Diamond, S. Martin, S. Hay, V. Liapis, I. Zinonos, N. A. Sims, G. J. Atkins, C. Vincent, V. Ponomarev, et al. Apo2L/TRAIL Inhibits Tumor Growth and Bone Destruction in a Murine Model of Multiple Myeloma Clin. Cancer Res., March 15, 2009; 15(6): 1998 - 2009. [Abstract] [Full Text] [PDF]

				Y. Han, Q. Guo, M. Zhang, Z. Chen, and X. Cao CD69+CD4+CD25- T Cells, a New Subset of Regulatory T Cells, Suppress T Cell Proliferation through Membrane-Bound TGF-{beta}1 J. Immunol., January 1, 2009; 182(1): 111 - 120. [Abstract] [Full Text] [PDF]

				H. Li, Y. Han, Q. Guo, M. Zhang, and X. Cao Cancer-Expanded Myeloid-Derived Suppressor Cells Induce Anergy of NK Cells through Membrane-Bound TGF-{beta}1 J. Immunol., January 1, 2009; 182(1): 240 - 249. [Abstract] [Full Text] [PDF]

				H. Jin, R. Yang, J. Ross, S. Fong, R. Carano, K. Totpal, D. Lawrence, Z. Zheng, H. Koeppen, H. Stern, et al. Cooperation of the Agonistic DR5 Antibody Apomab with Chemotherapy to Inhibit Orthotopic Lung Tumor Growth and Improve Survival Clin. Cancer Res., December 1, 2008; 14(23): 7733 - 7740. [Abstract] [Full Text] [PDF]

				J. H. Song, K. Kandasamy, and A. S. Kraft ABT-737 Induces Expression of the Death Receptor 5 and Sensitizes Human Cancer Cells to TRAIL-induced Apoptosis J. Biol. Chem., September 5, 2008; 283(36): 25003 - 25013. [Abstract] [Full Text] [PDF]

				A. Ashkenazi, P. Holland, and S. G. Eckhardt Ligand-Based Targeting of Apoptosis in Cancer: The Potential of Recombinant Human Apoptosis Ligand 2/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (rhApo2L/TRAIL) J. Clin. Oncol., July 20, 2008; 26(21): 3621 - 3630. [Abstract] [Full Text] [PDF]

				E. Contassot, K. Kerl, S. Roques, R. Shane, O. Gaide, M. Dupuis, A. H. Rook, and L. E. French Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sezary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression Blood, May 1, 2008; 111(9): 4780 - 4787. [Abstract] [Full Text] [PDF]

				X. Zhang, W. Li, and A. F. Olumi Low-Dose 12-O-Tetradecanoylphorbol-13-Acetate Enhances Tumor Necrosis Factor Related Apoptosis-Inducing Ligand Induced Apoptosis in Prostate Cancer Cells Clin. Cancer Res., December 1, 2007; 13(23): 7181 - 7190. [Abstract] [Full Text] [PDF]

				J. H. Song, M. C.L. Tse, A. Bellail, S. Phuphanich, F. Khuri, N. M. Kneteman, and C. Hao Lipid Rafts and Nonrafts Mediate Tumor Necrosis Factor Related Apoptosis-Inducing Ligand Induced Apoptotic and Nonapoptotic Signals in Non Small Cell Lung Carcinoma Cells Cancer Res., July 15, 2007; 67(14): 6946 - 6955. [Abstract] [Full Text] [PDF]

				W. Li, X. Zhang, and A. F. Olumi MG-132 Sensitizes TRAIL-Resistant Prostate Cancer Cells by Activating c-Fos/c-Jun Heterodimers and Repressing c-FLIP(L) Cancer Res., March 1, 2007; 67(5): 2247 - 2255. [Abstract] [Full Text] [PDF]

				W. S. Tsai, W.-S. Yeow, A. Chua, R. M. Reddy, D. M. Nguyen, D. S. Schrump, and D. M. Nguyen Enhancement of Apo2L/TRAIL-mediated cytotoxicity in esophageal cancer cells by cisplatin Mol. Cancer Ther., December 1, 2006; 5(12): 2977 - 2990. [Abstract] [Full Text] [PDF]

				S. Frese, M. Frese-Schaper, A.-C. Andres, D. Miescher, B. Zumkehr, and R. A. Schmid Cardiac Glycosides Initiate Apo2L/TRAIL-Induced Apoptosis in Non-Small Cell Lung Cancer Cells by Up-regulation of Death Receptors 4 and 5 Cancer Res., June 1, 2006; 66(11): 5867 - 5874. [Abstract] [Full Text] [PDF]

				L. M. Thai, A. Labrinidis, S. Hay, V. Liapis, S. Bouralexis, K. Welldon, B. J. Coventry, D. M. Findlay, and A. Evdokiou Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model. Cancer Res., May 15, 2006; 66(10): 5363 - 5370. [Abstract] [Full Text] [PDF]

				E. K. Rowinsky Targeted Induction of Apoptosis in Cancer Management: The Emerging Role of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Activating Agents J. Clin. Oncol., December 20, 2005; 23(36): 9394 - 9407. [Abstract] [Full Text] [PDF]

				L. Galligan, D. B. Longley, M. McEwan, T. R. Wilson, K. McLaughlin, and P. G. Johnston Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP Mol. Cancer Ther., December 1, 2005; 4(12): 2026 - 2036. [Abstract] [Full Text] [PDF]